HeaAstranalthcare firm misses Q3 revenue expectations

Astrana Health

06/11/2025 22:00

Overview

Astrana Q3 revenue doubles yr/yr but misses analyst expectations

Adjusted EBITDA for Q3 rises 52% to $68.5 mln, at higher end of guidance

Company completes Prospect Health acquisition, performance exceeds expectations

Outlook

Astrana updates full-year 2025 guidance due to full-risk contract delays

Company expects full-year 2025 revenue between $3.1 bln and $3.18 bln

Astrana anticipates full-year 2025 adjusted EBITDA between $200 mln and $210 mln

Result Drivers

PROSPECT HEALTH ACQUISITION - Acquisition of Prospect Health exceeded performance expectations, contributing to revenue growth and expanded operational scale

MEDICAL COST CONTROL - Co continues to control medical costs effectively, reiterating full-year trend expectations

STRATEGIC PARTNERSHIP - Partnership with Intermountain Health aims to expand access to coordinated care and enhance healthcare infrastructure

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$897.73 mln
$952.79 mln (8 Analysts)
Q3 EPS
$0.01
Q3 Income from Operations
$25.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Astrana Health Inc is $45.00, about 26.1% above its November 5 closing price of $33.24

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nPn9hhZqla

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)